Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately
ablative) will result in successful bone marrow replacement without as severe side-effects
but with permanent control of the disease. Patients will receive a chemotherapy regimen with
busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a
family-related or cord-blood matched donor.